cardiovascular-agents and Hemangioma--Cavernous--Central-Nervous-System

cardiovascular-agents has been researched along with Hemangioma--Cavernous--Central-Nervous-System* in 1 studies

Reviews

1 review(s) available for cardiovascular-agents and Hemangioma--Cavernous--Central-Nervous-System

ArticleYear
Could propranolol be beneficial in adult cerebral cavernous malformations?
    Neurosurgical review, 2019, Volume: 42, Issue:2

    Surgery is the only therapeutic option for cerebral cavernous malformations (CCM) and is proposed, whenever possible, after haemorrhagic events, neurological symptoms, or epilepsy, radiosurgery being a controversial alternative in some cases. However, there is no treatment for non-accessible lesions, such as brainstem CCM, multiple CCM, or those located in functional areas. Propranolol, a non-selective beta-blocker used as first-line treatment for infantile haemangiomas, has proved spectacularly effective in a few cases of adult patients with CCM. We herein review the histological, in vitro data and clinical findings that support the idea of propranolol as a potential treatment for CCM. Since one retrospective study has not been conclusive, we support the idea that prospective trials are necessary.

    Topics: Adrenergic beta-Antagonists; Brain Neoplasms; Cardiovascular Agents; Hemangioma, Cavernous, Central Nervous System; Humans; Propranolol

2019